About Hereditary Spastic Paraplegia
Hereditary spastic paraplegias (HSPs) are a clinically and genetically heterogeneous group of neurodegenerative disorders unified by progressive lower limb spasticity due to corticospinal tract degeneration. Over 80 genetic subtypes (SPG1-SPG86+) have been identified. Pure HSP involves spasticity and mild proprioceptive sensory loss; complicated HSP includes additional features such as intellectual disability, cerebellar ataxia, peripheral neuropathy, or thin corpus callosum. SPG4 (SPAST) is the most common, accounting for ~40% of autosomal dominant HSP.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Hereditary Spastic Paraplegia trials.
HSP subtype must be genetically confirmed — SPG4 (SPAST) trials differ from SPG11 or CYP7B1 trials
Spastic Paraplegia Rating Scale (SPRS) is the primary outcome measure — baseline score should be documented
Spasticity assessments (Modified Ashworth Scale) and gait analysis are standard baseline eligibility measures
Complicated HSP subtypes (SPG11, SPG15) may qualify for leukodystrophy or thin corpus callosum trials as well
Patient Resources
Find recruiting Hereditary Spastic Paraplegia trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Hereditary Spastic Paraplegia. Updated daily.